CLAIMS

1. An isolated antibody, or antigen-binding portion thereof, wherein said antibody, or antigen-binding portion comprises:

(a) an H-CDR1 as set forth in SEQ ID NO:29;

(b) an H-CDR2 as set forth in SEQ ID NO:30;

(c) an H-CDR3 as set forth in SEQ ID NO:31;

(d) an L-CDR1 as set forth in SEQ ID NO:34;

(e) an L-CDR2 as set forth in SEQ ID NO:35; and

(f) an L-CDR3 as set forth in SEQ ID NO:36.

2. The antibody, or antigen-binding portion according to claim 1 wherein said antibody, or antigen-binding portion comprises a V_H region amino acid sequence as set forth in SEQ ID NO:43.

3. The antibody, or antigen-binding portion according to claim 1 wherein said antibody, or antigen-binding portion comprises a V_L region amino acid sequence as set forth in SEQ ID NO:45.

4. The antibody, or antigen-binding portion according to claim 1, comprising a V_H region amino acid sequence as set forth in SEQ ID NO:43 and a V_L region amino acid sequence as set forth in SEQ ID NO:45.

5. The isolated antibody, wherein said antibody comprises a heavy chain amino acid sequence as set forth in SEQ ID NO:44 and further comprises a light chain amino acid sequence set forth in SEQ ID NO:46, with the proviso that the C-terminal lysine residue of SEQ ID NO:44 is optionally absent.

6. The isolated antibody according to any of claims 1 to 5, which is an IgG2.

7. A pharmaceutical composition comprising an antibody, or antigen-binding portion thereof, according to claims 1-6 and a pharmaceutically acceptable carrier.

CLAIMS

1. An invention not claimed in any divisional application.